Chen Zhang

Dr. Chen Zhang

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CZChen Zhang
Chen Zhang
JSJiong Shi
Jiong Shi
Intracranial vessel wall lesions are involved in a variety of neurological diseases. The advanced technique 7T MRI provides greater efficacy in the diagnosis of the pathology changes in the vessel wall and helps to identify potential subtle lesions. The purpose of this literature review was to systematically describe and evaluate the existing literature focusing on the use of 7T MRI in the detection and characterization of intracranial vessel wall lesions and their associated neurological disorders, to highlight the current knowledge gaps, and to formulate a framework to guide future applications and investigations. We systematically reviewed the existing articles up to July 2021, seeking the studies that assessed intracranial vessel wall lesions and their associated neurological disorders using 7T MRI. The literature search provided 12 studies that met the inclusion criteria. The most common intracranial vessel wall lesions were changes related to intracranial atherosclerosis (n = 8) and aneurysms (n = 4), such as intracranial atherosclerosis burden and aneurysm wall enhancement. The associated neurological disorders included aneurysms, ischemic stroke or TIA, small vessel disease, cognitive decline, and extracranial atherosclerosis. No paper studied the use of 7T MRI for investigating vessel wall conditions such as moyamoya disease, small vessel disease, or neurological disorders related to central nervous vasculitis. In conclusion, the novel 7T MRI enables the identification of a wider spectrum of subtle changes and associations. Future research on cerebral vascular diseases other than intracranial atherosclerosis and aneurysms may also benefit from 7T MRI.

25 April 2023 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
CZChen Zhang
Chen Zhang
SLShiping Li
Shiping Li
YWYongjun Wang
Yongjun Wang
JSJiong Shi
Jiong Shi
Background Small subcortical infarcts account for up to 25% of ischaemic strokes. Thalamus is one of the subcortical structures that commonly manifest with lacunar infarcts on MRI of the brain. Studies have shown that thalamus infarction is associated with cognitive decline. However, due to the lack of proper animal models, little is known about the mechanism. We aimed to establish a focal thalamus infarction model, characterise the infarct lesion and assess functional effects. Methods Male C57BL/6J mice were anaesthetised, and Rose Bengal dye was injected through the tail vein. The right thalamus was illuminated with green laser light by stereotactic implantation of optic fibre. Characteristics of the infarct and lesion evolution were evaluated by histological analysis and 7T MRI at various times. The cognitive and neurological functions were assessed by behavioural tests. Retrograde tracing was performed to analyse neural connections. Results An ischaemic lesion with small vessel occlusion was observed in the thalamus. It became a small circumscribed infarct with reactive astrocytes accumulated in the infarct periphery on day 21. The mice with thalamic infarction demonstrated impaired learning and memory without significant neurological deficits. Retrogradely labelled neurons in the retrosplenial granular cortex were reduced. Conclusion This study established a mouse model of thalamic lacunar infarction that exhibits cognitive impairment. Neural connection dysfunctions may play a potential role in post-stroke cognitive impairment. This model helps to clarify the pathophysiology of post-stroke cognitive impairment and to develop potential therapies.

1 January 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
XCXuhui Chen
Xuhui Chen
MJMingxing Jiang
Mingxing Jiang
LZLaihong Zhang
Laihong Zhang
JZJiayi Zhu
Jiayi Zhu
ALAnqi Li
Anqi Li
GLGuoyu Lan
Guoyu Lan
Plasma phosphorylated tau (p-tau) and β-amyloid (Aβ) are promising biomarkers for Alzheimer's disease (AD). However, it remains unclear whether combining p-tau with Aβ provides better predictive performance than using p-tau alone. To evaluate the predictive utility of plasma p-tau and Aβ combinations for AD-related pathology, brain atrophy, and cognitive decline. This study included 352 participants from the Greater-Bay Area Healthy Aging Brain Study (GHABS) cohort in China, classified into 227 Aβ-negative and 125 Aβ-positive individuals. Participants underwent Aβ positron emission tomography (PET) and plasma biomarker assessments. Plasma concentrations of p-tau181, p-tau217, p-tau231, Aβ42, and Aβ40 were quantified on the Quanterix HD-X and Lumipulse G1200 platform. Among the individual plasma p-tau variants, p-tau217 consistently outperformed p-tau181 and p-tau231. The combination of p-tau biomarkers (p-tau181, p-tau217, and p-tau231) with Aβ42 or the Aβ42/40 ratio further improved discrimination between Aβ+/CU (cognitively unimpaired) and Aβ-/CU individuals. Both p-tau/Aβ42 and p-tau/(Aβ42/40) exhibited slightly stronger or comparable associations with Aβ PET burden, baseline and longitudinal measures of hippocampal atrophy, AD-typical cortical thinning, and cognitive decline, relative to p-tau alone. The head-to-head comparisons indicate that p-tau217 is the most robust biomarker among the variants tested, and p-tau/Aβ ratios perform comparably or slightly better than p-tau alone in reflecting AD pathology, potentially providing complementary information for early detection and monitoring of disease progression.

5 June 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
CZChen Zhang
Chen Zhang
XCXuhui Chen
Xuhui Chen
YSYongan Sun
Yongan Sun
Alzheimer's disease and other dementias (ADODs) are increasingly becoming a major public health concern in rapidly ageing Asia. We compared the disease burden across Japan, China, and India at different demographic stages. The Global Burden of Disease Study of 2023 was used to analyze the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in 1990–2023. Decomposition analysis identified drivers of DALYs trends. DALYs associated risk factors were quantified. The Auto-Regressive Integrated Moving Average model was used to predict future disease burden. In 2023, China had the highest absolute burden, with age-standardized incidence and prevalence rates of 156.63 (95% uncertainty interval [UI]: 136.58–175.49) and 918.83(95% UI: 784.59–1,058.24) per 100,000, respectively. Japan recorded the highest age-standardized mortality rate (31.25 [8.47–71.42] per 100,000). India had the highest annual increase in mortality and DALYs, with estimated annual percentage changes of 0.91 (95% confidence interval [95% CI] 0.80–1.03) and 0.51 (0.45–0.56), respectively. Decomposition analysis revealed distinct drivers: Japan was dominated by epidemiological changes; China was driven by both aging and epidemiological changes; India was mainly due to population growth and epidemiological changes. Ambient particulate matter was the leading risk factor across all countries, though India faced a unique household air pollution burden. DALYs are predicted to increase in all three countries significantly by 2038. The ADODs burden remains substantial, driven by distinct demographic and epidemiological factors in Japan, China, and India. Tailored strategies for prevention and management are essential to address the growing burden.

18 June 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CWChengzhe Wang
Chengzhe Wang
CZChen Zhang
Chen Zhang
HLHailong Li
Hailong Li
LWLitao Wang
Litao Wang
XCXuhui Chen
Xuhui Chen
ADAilian Du
Ailian Du
Background: In cerebral small vessel disease (CSVD), the burden of white matter hyperintensities (WMH) does not fully account for cognitive impairment, suggesting the involvement of intermediary mechanisms. Objective: We investigated whether a gray matter atrophy network acts as the key mediator linking topologically specific (deep) WMH to multidomain cognitive dysfunction. Methods: In this retrospective study, 260 patients with CSVD (62 cognitively normal, 125 with mild impairment, 73 with dementia) were included. Cognitive status was assessed neuropsychologically. 3.0 T MRI identified an atrophy network. We then conducted pre-specified mediation analyses and a primary confirmatory analysis using structural equation modeling (SEM) to test whether this atrophy network mediated the effect of deep WMH on cognitive performance. Results: A 41-region atrophy network was identified , primarily involving the medial temporal lobe and thalamus, that was significantly associated with cognitive status. The final SEM demonstrated excellent fit, showing that higher deep WMH burden was associated with greater network atrophy ( β = 0.145, p < 0.05), which in turn was strongly associated with poorer executive function ( β = −0.64, p < 0.001) and memory ( β = −0.572, p < 0.001). The direct effect of WMH on cognition was not statistically significant in the model. Conclusions: Our findings suggest that in CSVD, a unified network of gray matter atrophy acts as a powerful statistical mediator in the effect of deep white matter injury on cognitive decline. This atrophy pattern may represent a more direct biomarker of the neurodegenerative process underlying cognitive impairment than WMH burden alone.

23 September 2026 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
LXLinhong Xu
Linhong Xu
JTJianbo Tu
Jianbo Tu
JZJipeng Zhang
Jipeng Zhang
CZChen Zhang
Chen Zhang
YSYongan Sun
Yongan Sun
The integration of blood-based biomarkers and artificial intelligence (AI) is revolutionizing the diagnostic landscape of Alzheimer’s disease (AD). In this paper, we synthesize recent advancements in the application of machine learning (ML) on blood biomarker analysis, evaluating their diagnostic efficacy and clinical translational potential. Current evidence identifies plasma p-tau217 as the best individual biomarker for primary screening. However, multiple biomarker signatures (such as A/T/N) combined with ML algorithms (like XGBoost) greatly improve diagnostic accuracy for mild cognitive impairment. Notably, predictive performance is maximized with multimodal fusion, which integrates data from blood, neuroimaging, and genetics, achieving an area under the curve of up to 0.94. To mitigate the black-box nature of these models, explainable AI frameworks like SHapley Additive exPlanations (SHAP) are essential for establishing clinical interpretability. Ultimately, we propose a scalable “Step-Care” framework that transitions from single-biomarker community screening to precise multimodal fusion, optimizing clinical trial stratification and personalized workflows.